Mylan Loses Fight For Generic Hypertension Drug

Law360 (February 27, 2007, 12:00 AM EST) -- Dealing a blow to generic drug maker Mylan Laboratories Inc., a federal judge in Pennsylvania has upheld Pfizer Inc.’s patent covering the key ingredient in its popular hypertension drug, Norvasc.

Mylan failed to persuade Judge Terrence F. McVerry of the U.S. District Court for the Western District of Pennsylvania that three claims of Pfizer’s patent were invalid based on an argument of obviousness.

McVerry determined Tuesday that Pfizer’s patent covering amlodipine besylate is valid, enforceable and would be infringed by Mylan’s generic product. The judge barred...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.